OpenAI acquires Orchestra Bio to connect research AI with drug-development operations
OpenAI is bringing Orchestra Bio's drug-development coordination platform and founder Ashoka Rajendra into Rosalind, its life-sciences AI business.
Fire or Trash?
Your verdict on this story. One tap, no account needed.Dumpster Fire links to reporting from RuntimeWire. We don’t rewrite the facts; the original story is one click away.
Comments
Loading comments…
Comments are automatically checked for hate, threats and spam. Community rules.